Skip to content
819 Capital Partners
  • About us
    • About us
    • Team
    • Vision
  • Portfolio
  • Activities
    • Venture Capital
    • Private Equity
    • M&A and Valuation
  • Funds
    • 819 Seed Fund I
    • 819 Evergreen Fund I
    • 819 Private Equity Fund I
  • News
  • Contact us

819 Capital Partners

  • About us
    • About us
    • Team
    • Vision
  • Portfolio
  • Activities
    • Venture Capital
    • Private Equity
    • M&A and Valuation
  • Funds
    • 819 Seed Fund I
    • 819 Evergreen Fund I
    • 819 Private Equity Fund I
  • News
  • Contact us
Linkedin

Portfolio

All 819 Evergreen Fund I819 Private Equity Fund IExit
NovioScan 819 Evergreen Fund IExit

NovioScan

Novioscan is founded in 2014 and holds its office at the NovioTech Campus in Nijmegen, The Netherlands. The development of wearable ultrasound devices was a result…

More information
Eurekite 819 Evergreen Fund I

Eurekite

Eurekite’s activities are all focused on its core invention: Flexiramics®. It is a flexible pure ceramic fiber mat that is light and flexible like paper, but…

More information
Neuroplast 819 Evergreen Fund I

Neuroplast

Neuroplast is a clinical stage biotech that develops the stem cell product Neuro-Cells®

More information
Atro Medical 819 Evergreen Fund I

Atro Medical

The company is addressing a large unmet medical need, as the number of patients with knee pain caused by a meniscectomy increase.

More information
TravelC Group 819 Private Equity Fund I

TravelC Group

Under the flag of TravelC Group, a company has been established for several internationally operating leisure brands. The Group consists of several complementary companies that facilitate…

More information
  • First
  • <
  • 01
  • 02
  • 03
  • Last

819 Capital Partners

  • Home
  • About us
  • Team
  • Memberships
  • Vision
  • Portfolio
  • News
  • Contact us

Member

Activities

  • Venture Capital
  • Private Equity
  • M&A and Valuation

Would you like more info?

info@819-capital.com Contact us

Follow us

Linkedin
© 2025 819 Capital Partners
  • |Terms & Conditions
  • |Privacy Policy
  • |ESG policy
  • |Realisatie Baas interactive